We previously reported that histamine H 3 receptors (H 3 Rs) are present in cardiac sympathetic nerve endings (cSNE) of animals and humans, where they attenuate norepinephrine (NE) release in normal and hyperadrenergic states, such as myocardial ischemia. The recent creation of a transgenic line of mice lacking H 3 R provided us with the opportunity to assess the relevance of H 3 R in the ischemic heart. We isolated SNE from hearts of wild-type (H 3 R ϩ/ϩ ) and knockout (H 3 R Ϫ/Ϫ ) mice and found that basal NE release from H 3 R Ϫ/Ϫ cSNE was ϳ60% greater than that from H 3 R ϩ/ϩ cSNE. NE exocytosis evoked by K ϩ -induced depolarization of cSNE from H 3 R
Sympathetic overactivity accompanied by excessive norepinephrine (NE) release is clinically recognized as a major cause of arrhythmic cardiac dysfunction in myocardial ischemia (Braunwald and Sobel, 1988; Kurz et al., 1991; Dart and Du, 1993; Kubler and Strasser, 1994; Benedict et al., 1996) . Indeed, myocardial infarction is often accompanied by arrhythmias with high morbidity and mortality (Braunwald and Sobel, 1988; Schomig et al., 1995; Airaksinen, 1999) . Sympathetic overactivity and excessive NE release increase metabolic demand, thereby aggravating the primary ischemia and initiating a vicious cycle that can culminate in further myocardial damage and severe cardiac failure (Kubler and Strasser, 1994) . Moreover, once released, NE enhances intracellular Ca 2ϩ by increasing its influx through voltage-dependent channels, mobilizing it from intracellular stores and favoring its inward transport by the Na ϩ /Ca 2ϩ exchanger. Ca 2ϩ overload eventually results in dysrhythmia and uncoordinated myocyte contraction (Levi and Smith, 2000) . Therefore, negative modulation of NE release from cardiac sympathetic nerves is a crucial protective mechanism.
We have shown that activation of histamine H 3 receptors (H 3 Rs) on cardiac sympathetic nerve endings (cSNE) negatively modulates NE release from ischemic hearts and attenuates the severity of associated ventricular arrhythmias (Levi and Smith, 2000) . H 3 Rs are but one of several classes of prejunctional heteroinhibitory receptors , and their efficacy in myocardial ischemia models has been tested to date only by pharmacological antagonism of their effects (Levi and Smith, 2000) . The availability of a newly created transgenic line of mice lacking H 3 R (Toyota et al., 2002) permits us to compare myocardial ischemia in the absence and presence of H 3 R and, thus, to evaluate the relevance of H 3 R as a basic modulatory mechanism of ischemic NE release. We report the novel finding that hearts with H 3 R deletion release more than twice as much NE when subjected to ischemia than hearts with intact H 3 R. This finding underscores the relevance of H 3 R as a major cardioprotective mechanism in myocardial ischemia. and pharmacological challenge as described previously (Toyota et al., 2002) . NE Release from Ischemic Mouse Hearts. Male wild-type H 3 R ϩ/ϩ (body weight, 26.6 Ϯ 0.4 g; heart weight, 141 Ϯ 3 mg; n ϭ 49) and knockout H 3 R Ϫ/Ϫ mice (body weight, 27.2 Ϯ 0.4 g; heart weight, 144 Ϯ 2 mg; n ϭ 35) were killed by cervical dislocation under light anesthesia with CO 2 vapor in accordance with institutional guidelines. The ribcage was dissected away, and the heart was rapidly excised, freed from fat and connective tissue and transferred to a Langendorff apparatus. The aorta was cannulated with a flanged 18-gauge stainless-steel needle. Spontaneously beating hearts were perfused through the aorta in a retrograde mode at a constant pressure of 100 cm of H 2 O with modified Krebs-Henseleit buffer (KHB) containing 120 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl 2 , 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 25 mM NaHCO 3 , 11 mM glucose, and 0.5 mM EDTA. The perfusion fluid was equilibrated with 95% O 2 /5% CO 2 at 37°C to give a pH of 7.4. After a 30-min stabilization period, normothermic ischemia was induced by perfusing hearts for 20 min with glucose-free KHB equilibrated with 95% N 2 and 5% CO 2 and containing the reducing agent sodium dithionite (final concentration of 0.25 mM). Hearts receiving drug treatment were treated for 15 min before induction of ischemia. The coronary effluent was collected into tubes. In the preischemic and ischemic periods, tubes were replaced every 5 min. The volume of effluent collected for each period was weighed and subsequently analyzed for NE content. All drugs were added to the perfusion solution. NE was assayed in the coronary perfusate by high-pressure liquid chromatography with electrochemical detection (Silver et al., 2002) .
NE Release from Cardiac Synaptosomes. Cardiac synaptosomes were isolated as described previously for the guinea pig (Seyedi et al., 1997; Silver et al., 2002) . Briefly, hearts from 20 H 3 R ϩ/ϩ and 20 H 3 R Ϫ/Ϫ mice were excised as described above and transferred to a Langendorff apparatus. Spontaneously beating hearts were perfused through the aorta for 15 min at constant pressure (100 cm of H 2 O) with modified KHB at 37°C saturated with 95% O 2 and 5% CO 2 , pH 7.4. This procedure ensured that no blood traces remained in the coronary circulation. At the end of the 15-min perfusion, hearts were minced in ice-cold 0.32 M sucrose containing 1 mM EGTA, pH 7.4. Minced tissue was digested with 40 mg collagenase (type II; Worthington Biochemicals, Freehold, NJ) per 10 ml of 0.32 M sucrose solution per gram of wet heart weight for 1 h at 37°C. The sucrose solution contained 1 mM pargyline to prevent enzymatic destruction of synaptosomal NE. After low-speed centrifugation (10 min at 120g and 4°C), the resulting pellet was suspended in 10 volumes of 0.32 M sucrose and homogenized with a Teflon/glass homogenizer. The homogenate was spun at 650g for 10 min at 4°C, and the pellet was rehomogenized and respun. The pellet containing cellular debris was discarded, and the supernatants from the last two spins were combined and equally subdivided into four tubes. Each tube was centrifuged for 20 min at 20,000g at 4°C. This pellet, which contained cardiac synaptosomes, was resuspended in Hepesbuffered saline to a final volume of 500 l in the presence or absence of pharmacological agents for a total of 20 min in a water bath at 37°C. Each suspension functioned as an independent sample and was used only once. In every experiment, one sample was untreated (control, basal NE release), and others were incubated with drugs for 20 min. When antagonists were used, samples were incubated with the antagonist for 20 min before incubation with the agonist. Controls were incubated for an equivalent length of time without drugs. At the end of the incubation period, each sample was centrifuged for 20 min (20,000g at 4°C). The supernatant was assayed for NE content by high-pressure liquid chromatography as described above, and the pellet was assayed for protein content by a modified Lowry procedure (Silver et al., 2002) . Although the presence of sympathetic nerve endings in the synaptosomal preparation was not verified by electron microscopy, murine cardiac synaptosomes responded to K ϩ depolarization with NE release, which was inhibited by selective H 3 R and A 1 R activation (as described under Results). This response was indistinguishable from that observed in the same preparation from the guinea pig heart (Seyedi et al., 1997) , whose synaptosomal composition had been ascertained by electron microscopy (R. Levi and N. Seyedi, unpublished observations).
Statistics. Values are expressed as the mean percentage increases above basal NE release (synaptosomes) or as absolute values for NE overflow (isolated hearts) Ϯ S.E.M. Analysis by one-way ANOVA was used, followed by post hoc testing (Dunnett's test). A p value of Ͻ0.05 was considered statistically significant.
Results
Exocytosis of Endogenous Norepinephrine from Cardiac Sympathetic Nerve Terminals. As we did previously with human (Imamura et al., 1995) , guinea pig (Seyedi et al., 1997) , and dog (Seyedi et al., 1996) cardiac tissue, we first assessed whether the mouse heart harbors H 3 inhibitory heteroreceptors located prejunctionally on SNE. For this, we studied the action of the selective H 3 R agonist imetit (Garbarg et al., 1992 ) directly on SNE (cardiac synaptosomes) isolated from wild-type (H 3 R ϩ/ϩ ) mouse hearts. As shown in Fig. 1, A and B, depolarization of mouse cSNE with 100 mM K ϩ resulted in a ϳ20 to 30% increase in NE release above the basal level of 0.76 Ϯ 0.11 pmol/mg (mean Ϯ S.E.M.; n ϭ 20). When cSNE were pretreated with imetit (100 nM), NE release in response to K ϩ -induced depolarization was reduced by ϳ50%. This effect of imetit was prevented by pretreatment with the selective H 3 R antagonist thioperamide (Arrang et al., 1987) (300 nM) (Fig. 1A) . We also determined the presence of other prejunctional inhibitory heteroreceptors in the cSNE of H 3 R ϩ/ϩ mice. As shown in Fig. 1B , the selective adenosine A 1 receptor (A 1 R) agonist N 6 -cyclopentyladenosine (CPA; 300 nM) (Barrett et al., 1994) decreased K ϩ -induced NE release by ϳ70%. This effect of CPA was prevented by pretreatment with the selective A 1 R antagonist 3-cyclopentyl-1,3-dipropylxanthine (DPCPX) (300 nM) (Haleen et al., 1987) (Fig. 1B) .
As shown in Fig. 1 , C and D, K ϩ -induced depolarization of cSNE isolated from hearts of mice lacking H 3 R (H 3 R Ϫ/Ϫ ) resulted in a ϳ25 to 35% increase in NE release above the basal level of 1.25 Ϯ 0.06 pmol/mg (mean Ϯ S.E.M.; n ϭ 20). Notably, this basal level was ϳ60% greater than that for synaptosomes isolated from H 3 R ϩ/ϩ mouse hearts (p Ͻ 0.01). Contrary to its action on SNE from H 3 R ϩ/ϩ mouse hearts, imetit failed to modify the K ϩ -induced NE release in SNE isolated from H 3 R Ϫ/Ϫ mouse hearts (Fig. 1C) . However, in H 3 R Ϫ/Ϫ cSNE, activation of A 1 R with CPA still caused a ϳ70% reduction in K ϩ -induced NE release, which was prevented by pretreatment with DPCPX (Fig. 1D) . This suggested that although H 3 R-mediated modulation of NE exocytosis had been deleted in H 3 R Ϫ/Ϫ mouse hearts, A 1 Rmediated modulation was preserved.
Release of Endogenous Norepinephrine from the Ischemic Heart. Inasmuch as these findings indicated the absence of inhibitory H 3 R on cSNE of H 3 R Ϫ/Ϫ mice, we next questioned whether such an absence might influence NE release in myocardial ischemia, given that H 3 R are known to negatively modulate NE release in this condition (Levi and Smith, 2000 ischemic conditions (glucose-free buffer containing the reducing agent sodium dithionite and equilibrated with 95% N 2 and 5% CO 2 ), total NE overflow increased to ϳ400 pmol/g ( Fig. 2A) . The NE transporter inhibitor desipramine (100 nM) markedly inhibited (ϳ50%) this increase in overflow ( Fig. 2A) , indicating that ischemic NE release was carriermediated; that is, NE was carried out of cSNE by the NE transporter in a reversed mode of action (Levi and Smith, 2000) . In hearts perfused with imetit (100 nM), ischemic NE overflow was reduced by ϳ40%. This effect was abolished in the presence of thioperamide (300 nM). In fact, with thioperamide, either alone or combined with imetit, ischemic NE overflow was ϳ35% greater than that in control conditions ( Fig. 2A) . In hearts perfused with CPA (100 nM), ischemic NE overflow was reduced by ϳ50%. This effect was abolished in the presence of DPCPX (100 nM). In marked contrast, when hearts from H 3 R Ϫ/Ϫ mice were perfused for 20 min in ischemic conditions, total NE overflow was more than 2-fold greater than in H 3 R ϩ/ϩ mouse hearts (p Ͻ 0.01) (Fig. 2B) . As in H 3 R ϩ/ϩ hearts, desipramine (100 nM) markedly inhibited (ϳ65%) this increase in overflow (Fig. 2B) , indicating that ischemic NE release in H 3 R Ϫ/Ϫ hearts was also carrier-mediated. However, neither imetit nor thioperamide modified ischemic NE overflow in H 3 R Ϫ/Ϫ hearts (Fig. 2B) . Similar to its action on H 3 R ϩ/ϩ hearts, CPA (100 nM) again reduced ischemic NE overflow by ϳ50%, an effect that was prevented by DPCPX (100 nM) (Fig. 2B) .
Discussion
In protracted myocardial ischemia, metabolic acidosis develops in SNE, leading to activation of the Na ϩ /H ϩ exchanger and, thus, to an increase in intraneuronal Na ϩ concentra- Fig. 1 . Exocytotic NE release from mouse heart sympathetic nerve endings (cardiac synaptosomes) depolarized with 100 mM K ϩ . Bars indicate the mean percentage increases in NE release above basal levels (Ϯ S.E.M.). Basal NE release was 0.76 Ϯ 0.11 and 1.25 Ϯ 0.06 pmol/mg protein for H 3 R ϩ/ϩ and H 3 R Ϫ/Ϫ , respectively (n ϭ 20 ϩ 20; p Ͻ 0.01). Drugs were administered at the following concentrations: imetit, 100 nM; thioperamide, 300 nM; CPA, 300 nM; and DPCPX, 300 nM. These data show that the H 3 R-mediated attenuation of NE exocytosis is lost in the synaptosomes of H 3 R Ϫ/Ϫ mice, whereas the modulatory activity of the adenosine A 1 R-agonist CPA is preserved. A total of 40 mouse hearts were used (n ϭ 8 -12 for each graph). *, significantly different from K ϩ alone by one-way ANOVA, followed by post hoc testing (Dunnett's test).
Fig. 2.
Carrier-mediated NE release from isolated ischemic mouse hearts. After a stabilization period, each of the 84 hearts was made globally ischemic by a 20-min perfusion with glucose-free KHS containing sodium dithionite 0.25 mM and bubbled with 95% N 2 plus 5% CO 2 . Bars are means Ϯ S.E.M. (n ϭ 5-11 per column). Control NE release represents the total amount of NE released in the 20-min ischemic period. This release was carrier-mediated because it was inhibited by the NE transporter blocker desipramine (DMI). Drugs were administered at the following concentrations: 100 nM DMI, 100 nM imetit, 300 nM thioperamide, 100 nM CPA, and 100 nM DPCPX. The data show that when subjected to ischemia, H 3 R Ϫ/Ϫ hearts release a 2-fold greater amount of NE than do H 3 R ϩ/ϩ hearts (p Ͻ 0.01), despite the fact the adenosinemediated modulatory system seems to be functioning as well in the H 3 R Ϫ/Ϫ as in the H 3 R ϩ/ϩ hearts. Note that the doubling of ischemic NE release in the H 3 R Ϫ/Ϫ hearts persists in the presence of imetit and thioperamide. *, significantly different from control by one-way ANOVA, followed by post hoc testing (Dunnett's test). tion. Also, because of ATP depletion and impaired NE storage in synaptic vesicles, NE accumulates in the axoplasm. These conditions force the reversal of the Na ϩ -dependent NE transporter in an outward direction, triggering a massive carriermediated release of NE and arrhythmias (Lameris et al., 2000; Levi and Smith, 2000; Akiyama and Yamazaki, 2001) . Indeed, NE overflow in myocardial ischemia directly correlates with the severity of arrhythmias Hatta et al., 1999; Maruyama et al., 1999) .
We had identified H 3 R as inhibitory heteroreceptors in adrenergic nerve endings of the heart (Endou et al., 1994) . We also established that in addition to inhibiting NE exocytosis from sympathetic nerve endings, selective H 3 R agonists attenuate carrier-mediated release of NE in both animal and human models of protracted myocardial ischemia Hatta et al., 1997) . We subsequently demonstrated that H 3 R-mediated attenuation of exocytotic NE release involves an inhibition of N-type Ca 2ϩ channels (Silver et al., 2002) , whereas H 3 R-mediated reduction of carriermediated NE release is associated with diminished Na ϩ /H ϩ exchanger activity Hatta et al., 1997; Silver et al., 2001) . Most important, by reducing ischemic NE release, H 3 R stimulation significantly attenuates the severity of ischemic arrhythmias Levi and Smith, 2000) .
Other presynaptic receptors, such as ␣ 2 adrenoceptors and A 1 R, also modulate NE release from cSNE (Seyedi et al., 1997 ). Yet, H 3 R stimulation attenuates both exocytotic and carrier-mediated NE release, whereas ␣ 2 -adrenoceptor agonists attenuate NE exocytosis but enhance carrier-mediated NE release . Furthermore, although A 1 R activation reduces both exocytotic and carrier-mediated NE release, A 1 R stimulation has negative chronotropic and dromotropic effects, whereas H 3 R agonists have no such effects (Levi and Smith, 2000) . Accordingly, because excess NE release can trigger severe arrhythmias and sudden cardiac death, we have proposed that negative modulation of NE release by H 3 R agonists may offer a novel therapeutic approach to myocardial ischemia (Levi and Smith, 2000; Mackins and Levi, 2000) .
The recent creation of a transgenic line of mice devoid of H 3 R (Toyota et al., 2002) provided us with the opportunity to assess the relevance of H 3 R in myocardial ischemia. Thus, we found that although cSNE isolated from wild-type mice responded to the H 3 R agonist imetit with a marked decrease in K ϩ -induced NE release, similar to what we had observed previously in SNE isolated from guinea pig, dog, and human hearts (Endou et al., 1994; Imamura et al., 1994 Imamura et al., , 1995 Seyedi et al., 1996; Hatta et al., 1997) , cSNE isolated from H 3 R Ϫ/Ϫ mice failed to respond to H 3 R agonists with an attenuation of NE exocytosis. Yet H 3 R Ϫ/Ϫ cSNE still responded to A 1 R agonists, as demonstrated by the fact that CPA attenuated equally effectively NE exocytosis in cSNE of H 3 R ϩ/ϩ and H 3 R Ϫ/Ϫ mice. These findings clearly indicate that H 3 R Ϫ/Ϫ mice are an ideal model for the verification of the postulated cardioprotective role of H 3 R located on cSNE.
Indeed, we found that in ischemic conditions, a lack of H 3 R in cSNE translated into a 2-fold increase in NE overflow from the hearts of H 3 R Ϫ/Ϫ mice compared with H 3 R ϩ/ϩ hearts. This is consistent with our previous findings in the guinea pig heart, in which the blockade of H 3 R with thioperamide doubled NE release during ischemia/reperfusion (Imamura et al., 1994) , and in a human model of myocardial ischemia, in which blockade of H 3 R with thioperamide or clobenpropit significantly increased NE release (Hatta et al., 1997) . The massive NE overflow from H 3 R Ϫ/Ϫ mouse hearts occurred despite the fact that inhibitory A 1 Rs were still functioning to attenuate both exocytotic and carrier-mediated NE release in the H 3 R Ϫ/Ϫ hearts. This clearly demonstrates that cSNE H 3 Rs play a relevant role in the modulation of NE release in myocardial ischemia.
Notably, the H 3 R antagonist thioperamide potentiated NE release from ischemic H 3 R ϩ/ϩ hearts but not from cSNE from normoxic H 3 R ϩ/ϩ hearts. This indicates that, as we had observed previously in guinea pig and human hearts, H 3 Rs located on cSNE become activated in conditions characterized by enhanced adrenergic activity, such as myocardial ischemia, when cSNE are exposed to functionally significant concentrations of histamine released from local mast cells by oxygen free radicals (Imamura et al., 1994; Hatta et al., 1997) . The fact that thioperamide failed to potentiate NE overflow from ischemic H 3 R Ϫ/Ϫ hearts further strengthens this notion. Basal NE release from cSNE isolated from H 3 R Ϫ/Ϫ was ϳ60% greater than that from cSNE isolated from H 3 R ϩ/ϩ hearts. This finding is consistent with a recent report of constitutive activity of native H 3 R in rodent brain (Morisset et al., 2000) .
Inasmuch as excessive NE release is recognized as a major cause of arrhythmic cardiac dysfunction in humans (Braunwald and Sobel, 1988; Dart and Du, 1993; Kubler and Strasser, 1994; Benedict et al., 1996) , our present and past findings reveal that H 3 R perform a crucial protective role in myocardial ischemia. This adds further strength to our notion (Levi and Smith, 2000; Mackins and Levi, 2000) that negative modulation of NE release by H 3 R agonists may offer a novel therapeutic approach to myocardial ischemia.
